Header Leaderboard Ad


Affy Sues Illumina in genome-analysis and array technologies



No announcement yet.
  • Filter
  • Time
  • Show
Clear All
new posts

  • Affy Sues Illumina in genome-analysis and array technologies

    Affy recently(Oct 26th, 2007) filed additional patent-infringement lawsuit against Illumina.

    See detail news:

    Due to significance of the decision, we will discuss about patent claims in near future.

  • #2
    Great topic to start off this forum, thanks B.

    This Forbes article has a bit more info, particularly the patent filings that Affy is claiming are infringed upon:

    In the new suits Affymetrix accuses Illumina of infringing US Patents No. 5,902,723, No. 6,403,320, No. 6,420,169, No. 6,576,424, and No. 7,056,666; and in the UK and Germany under European Patents No. 0834575, No. 0853679, and No. 0799897.
    Google patent links here:
    • 5,902,723: Analysis of surface immobilized polymers utilizing microfluorescence detection
    • 6,403,320: Support bound probes and methods of analysis using the same
    • 6,420,169: Apparatus for forming polynucleotides or polypeptides
    • 6,576,424: Arrays and methods for detecting nucleic acids
    • 7,056,666: Analysis of surface immobilized polymers utilizing microfluorescence detection

    There is a fair amount of information on Affy's investor webpage


    • #3
      Just to complete this discussion, it seems that the dispute was settled.

      Press Release on Affymetrix's web page

      and see also the thread started by ECO:
      The more you know, the more you know you don't know. —Aristotle


      • #4
        I am very interested in the impact of this patent dispute on users. Any comments will be appreciated!


        • #5
          I haven't felt any impact. What are some ways there may be an impact?
          Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.com


          • #6
            Maybe the effect was that some potential user/buyers were discouraged from buying Illumina because of the pending lawsuit during the litigation.

            For example, Affy was seeking an injunction against any sale of Illumina products. So if the injunction was approved by the court, the choice of Illumina may have seemed risky to buyers/users during the litigation.


            • #7
              We bought a GAII in early 2008, so were considering a purchase during this timeframe. I don't think it weighed heavily in the discussion for us. It seems that these large companies sue each other all the time, but nearly always find a way to continue doing business after some payment is made.
              Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.com


              • #8
                Thanks SNPsaurus for comment. So the many patent lawsuit are the games among manufacturers, and users in this market do not get affected. Very helpful!


                Latest Articles


                • seqadmin
                  A Brief Overview and Common Challenges in Single-cell Sequencing Analysis
                  by seqadmin

                  ​​​​​​The introduction of single-cell sequencing has advanced the ability to study cell-to-cell heterogeneity. Its use has improved our understanding of somatic mutations1, cell lineages2, cellular diversity and regulation3, and development in multicellular organisms4. Single-cell sequencing encompasses hundreds of techniques with different approaches to studying the genomes, transcriptomes, epigenomes, and other omics of individual cells. The analysis of single-cell sequencing data i...

                  01-24-2023, 01:19 PM
                • seqadmin
                  Introduction to Single-Cell Sequencing
                  by seqadmin
                  Single-cell sequencing is a technique used to investigate the genome, transcriptome, epigenome, and other omics of individual cells using high-throughput sequencing. This technology has provided many scientific breakthroughs and continues to be applied across many fields, including microbiology, oncology, immunology, neurobiology, precision medicine, and stem cell research.

                  The advancement of single-cell sequencing began in 2009 when Tang et al. investigated the single-cell transcriptomes
                  01-09-2023, 03:10 PM